Photocure ASA (OSL:PHO)

Norway flag Norway · Delayed Price · Currency is NOK
50.00
+0.10 (0.20%)
May 9, 2025, 4:25 PM CET
-15.25%
Market Cap 1.33B
Revenue (ttm) 532.69M
Net Income (ttm) 2.14M
Shares Out 26.61M
EPS (ttm) 0.08
PE Ratio 622.23
Forward PE 332.58
Dividend n/a
Ex-Dividend Date n/a
Volume 51,992
Average Volume 43,210
Open 50.10
Previous Close 50.00
Day's Range 49.70 - 50.30
52-Week Range 47.00 - 69.00
Beta 0.62
RSI 38.30
Earnings Date Apr 11, 2025

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Sector Healthcare
Founded 1993
Employees 101
Stock Exchange Oslo Børs
Ticker Symbol PHO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.